Bevacizumab (anti-VEGF) 216974-75-3

Bevacizumab (anti-VEGF)

询价 100mg 起订

500mg 起订

1000mg 起订

上海更新日期：2025-11-11

上海拓普韦尔生物医药科技有限公司

非会员

联系人：胡博

手机：13321917662 拨打

邮箱：sales@topwellpharma.com

产品详情:

中文名称：: 贝伐单抗

英文名称：: Bevacizumab (anti-VEGF)

CAS号：: 216974-75-3

品牌：: Topwell

产地：: 上海市

保存条件：: -30 ℃

纯度规格：: 98% SEC-HPLC

产品类别：: 生物类似抗体

靶点：: VEGF-A

生物作用：: Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that contains human framework regions and murine complementarity-determining regions.

应用：: Bevacizumab is vascular endothelial growth factor directed antibody.

Product Name: Bevacizumab (anti-VEGF) | RhuMab VEGF

CAS:216974-75-3

MW: 149 kDa

Storage condition:Sealed and stored at ≤-30℃, away from light. Avoid freeze-thaw cycles.
Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.
For research use only

Bevacizumab;216974-75-3;

公司简介

Shanghai Topwell Pharma Co., Ltd. is specialized in research, development, custom manufacturing and sales of APIs, Pharmaceutical Excipients, Health & Nutritional Ingredients, Polypeptides and Antibodies, etc.. Topwell has a professional R&D team. We have built close cooperative relationships with many research institutes and universities in China. In addition, we have very close cooperation relationships with many Chinese pharmaceutical factories. Topwell aims to become a global leader in pharmaceutical & chemical industry. 上海拓普韦尔生物医药科技有限公司专注于小分子药物发现领域的分子砌块和工具化合物的研究开发，为全球医药企业和科研机构提供从药物发现到原料药和医药中间体的规模化生产的相关产品和技术服务。

成立日期	(6年)
注册资本	300万人民币
员工人数	10-50人
年营业额	￥ 500万-1000万
经营模式	工厂,试剂,定制,服务
主营行业	标准品和对照品,医药中间体,癌症研究,生物活性小分子,诊断试剂